Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Accounts Payables (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Accounts Payables over the past 15 years, most recently at $8.2 million for Q2 2025.

  • Quarterly results put Accounts Payables at $8.2 million for Q2 2025, down 49.68% from a year ago — trailing twelve months through May 2025 was $8.2 million (down 49.68% YoY), and the annual figure for FY2025 was $8.2 million, down 49.68%.
  • Accounts Payables for Q2 2025 was $8.2 million at Lifecore Biomedical, Inc. \De\, up from $7.4 million in the prior quarter.
  • Over the last five years, Accounts Payables for LFCR hit a ceiling of $22.1 million in Q2 2023 and a floor of $7.4 million in Q1 2025.
  • Median Accounts Payables over the past 5 years was $13.3 million (2022), compared with a mean of $13.3 million.
  • Biggest five-year swings in Accounts Payables: plummeted 86.04% in 2021 and later surged 70.61% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Accounts Payables stood at $8.7 million in 2021, then surged by 53.68% to $13.3 million in 2022, then skyrocketed by 43.02% to $19.0 million in 2023, then decreased by 21.32% to $15.0 million in 2024, then tumbled by 45.08% to $8.2 million in 2025.
  • The last three reported values for Accounts Payables were $8.2 million (Q2 2025), $7.4 million (Q1 2025), and $15.0 million (Q4 2024) per Business Quant data.